[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].


The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; (1) MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multidrug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). (2) MEPM maintained potent and stable antibacterial activity against Pseudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. (3) The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-beta-lactamase strains was 2.0% (6 strains) in P. aeruginosa. (4) Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

Cite this paper

@article{Yamaguchi2011NationwideSO, title={[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].}, author={Keizo Yamaguchi and Yoshikazu Ishii and Morihiro Iwata and Naoki Watanabe and Masaaki Shinagawa and Minoru Yasujima and Akira Suwabe and Makiko Kuroda and Mitsuo Kaku and M. Kitagawa and Keiji Kanemitsu and Yuji Imafuku and M . M . Murakami and Sachie Yomodu and Nobuyuki Taniguchi and Toshiyuki Yamada and Fumio Nomura and Harushige Kanno and Shiegefumi Maesaki and Giichi Hashikita and Shigemi Kondo and Shigeki Misawa and Hajime Horiuchi and Yoko Tazawa and Hideki Nakashima and Hiromu Takemura and Masahiko Okada and Yoshinori Horikawa and Masato Maekawa and Osanori Nagura and Tetsuya Yagi and Hisashi Baba and Shiomi Ishigo and Naohisa Fujita and Toshiaki Komori and Satoshi Ichiyama and Kiyoharu Yamanaka and Yoko Murata and Shuji Matsuo and Hisashi Kohno and Seiji Kawano and Shohiro Kinoshita and Tomohiko Taminato and Kiyoshi Negayama and Mitsuharu Murase and Hitoshi Miyamoto and Nobuchika Kusano and Motoko Nose and Michiya Yokozaki and Hideyuki Itaha and Akira Matsunaga and Hisae Yoshimura and Shigeru Kohno and Katsunori Yanagihara and Junichi Matsuda and Tetsunori Saikawa and Kazufumi Hiramatsu}, journal={The Japanese journal of antibiotics}, year={2011}, volume={64 2}, pages={53-95} }